Literature DB >> 31431014

Structural Dynamics of Agonist and Antagonist Binding to the Androgen Receptor.

Ettayapuram Ramaprasad Azhagiya Singam1, Phum Tachachartvanich2, Michele A La Merrill2, Martyn T Smith3, Kathleen A Durkin1.   

Abstract

Androgen receptor (AR) is a steroid hormone nuclear receptor which upon binding its endogenous androgenic ligands (agonists), testosterone and dihydrotestosterone (DHT), alters gene transcription, producing a diverse range of biological effects. Antiandrogens, such as the pharmaceuticals bicalutamide and hydroxyflutamide, act as agonists in the absence of androgens and as antagonists in their presence or in high concentration. The atomic level mechanism of action by agonists and antagonists of AR is less well characterized. Therefore, in this study, multiple 1 μs molecular dynamics (MD), docking simulations, and perturbation-response analyses were performed to more fully explore the nature of interaction between agonist or antagonist and AR and the conformational changes induced in the AR upon interaction with different ligands. We characterized the mechanism of the ligand entry/exit and found that helix-12 and nearby structural motifs respond dynamically in that process. Modeling showed that the agonist and antagonist/agonist form a hydrogen bond with Thr877/Asn705 and that this interaction is absent for antagonists. Agonist binding to AR increases the mobility of residues at allosteric sites and coactivator binding sites, while antagonist binding decreases mobility at these important sites. A new site was also identified as a potential surface for allosteric binding. These results shed light on the effect of agonists and antagonists on the structure and dynamics of AR.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31431014      PMCID: PMC6742532          DOI: 10.1021/acs.jpcb.9b05654

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  54 in total

1.  How do substrates enter and products exit the buried active site of cytochrome P450cam? 1. Random expulsion molecular dynamics investigation of ligand access channels and mechanisms.

Authors:  S K Lüdemann; V Lounnas; R C Wade
Journal:  J Mol Biol       Date:  2000-11-10       Impact factor: 5.469

2.  Comparison of the dynamics of substrate access channels in three cytochrome P450s reveals different opening mechanisms and a novel functional role for a buried arginine.

Authors:  Peter J Winn; Susanna K Lüdemann; Ralph Gauges; Valère Lounnas; Rebecca C Wade
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

3.  Structural stability of binding sites: consequences for binding affinity and allosteric effects.

Authors:  I Luque; E Freire
Journal:  Proteins       Date:  2000

Review 4.  Is allostery an intrinsic property of all dynamic proteins?

Authors:  K Gunasekaran; Buyong Ma; Ruth Nussinov
Journal:  Proteins       Date:  2004-11-15

5.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

Authors:  Richard A Friesner; Jay L Banks; Robert B Murphy; Thomas A Halgren; Jasna J Klicic; Daniel T Mainz; Matthew P Repasky; Eric H Knoll; Mee Shelley; Jason K Perry; David E Shaw; Perry Francis; Peter S Shenkin
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

6.  Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort.

Authors:  C J Newschaffer; K Otani; M K McDonald; L T Penberthy
Journal:  J Natl Cancer Inst       Date:  2000-04-19       Impact factor: 13.506

7.  Cellular and molecular mechanisms of action of linuron: an antiandrogenic herbicide that produces reproductive malformations in male rats.

Authors:  C Lambright; J Ostby; K Bobseine; V Wilson; A K Hotchkiss; P C Mann; L E Gray
Journal:  Toxicol Sci       Date:  2000-08       Impact factor: 4.849

8.  Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor.

Authors:  David Masiello; Shinta Cheng; Glenn J Bubley; Michael L Lu; Steven P Balk
Journal:  J Biol Chem       Date:  2002-05-15       Impact factor: 5.157

9.  Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

Authors:  Takahito Hara; Jun-ichi Miyazaki; Hideo Araki; Masuo Yamaoka; Naoyuki Kanzaki; Masami Kusaka; Masaomi Miyamoto
Journal:  Cancer Res       Date:  2003-01-01       Impact factor: 12.701

10.  Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.

Authors:  Z Culig; J Hoffmann; M Erdel; I E Eder; A Hobisch; A Hittmair; G Bartsch; G Utermann; M R Schneider; K Parczyk; H Klocker
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

View more
  4 in total

1.  Predicting the binding of small molecules to nuclear receptors using machine learning.

Authors:  Azhagiya Singam Ettayapuram Ramaprasad; Martyn T Smith; David McCoy; Alan E Hubbard; Michele A La Merrill; Kathleen A Durkin
Journal:  Brief Bioinform       Date:  2022-05-13       Impact factor: 13.994

Review 2.  Steroids and TRP Channels: A Close Relationship.

Authors:  Karina Angélica Méndez-Reséndiz; Óscar Enciso-Pablo; Ricardo González-Ramírez; Rebeca Juárez-Contreras; Tamara Rosenbaum; Sara Luz Morales-Lázaro
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

3.  Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors.

Authors:  Mariia Radaeva; Huifang Li; Eric LeBlanc; Kush Dalal; Fuqiang Ban; Fabrice Ciesielski; Bonny Chow; Helene Morin; Shannon Awrey; Kriti Singh; Paul S Rennie; Nada Lallous; Artem Cherkasov
Journal:  Cells       Date:  2022-09-07       Impact factor: 7.666

4.  Molecular Image-Based Prediction Models of Nuclear Receptor Agonists and Antagonists Using the DeepSnap-Deep Learning Approach with the Tox21 10K Library.

Authors:  Yasunari Matsuzaka; Yoshihiro Uesawa
Journal:  Molecules       Date:  2020-06-15       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.